<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药物探索 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-16T23:53:53+08:00</updated>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>国内再来一款KRAS G12C，Enhertu新适应症获批。。。</title>
    <updated>2021-01-16T22:33:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/3ulf-78FKoEJIjS4_2MnxA</id>
    <link href="https://mp.weixin.qq.com/s/3ulf-78FKoEJIjS4_2MnxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内第3款MET/EGFR特异性双抗，MET/EGFR ADC会有吗？</title>
    <updated>2021-01-10T11:22:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/rfXi_7amS22hVFJfJBv_gg</id>
    <link href="https://mp.weixin.qq.com/s/rfXi_7amS22hVFJfJBv_gg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Fast Follow是什么，更多的仍是Me-too</title>
    <updated>2021-01-09T10:07:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-09:/s/8AhCh-521dP6Vf9z6qR5OA</id>
    <link href="https://mp.weixin.qq.com/s/8AhCh-521dP6Vf9z6qR5OA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>SHP2分子开发，下一步走向何方？</title>
    <updated>2021-01-03T11:05:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/FT41YY8jjXnbIrQ0IeG4ig</id>
    <link href="https://mp.weixin.qq.com/s/FT41YY8jjXnbIrQ0IeG4ig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>加科思SHP2数据公布，好还是不好呢？</title>
    <updated>2020-12-19T09:01:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/JOTL4Q69koHDssCq8pG4vg</id>
    <link href="https://mp.weixin.qq.com/s/JOTL4Q69koHDssCq8pG4vg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>你说价格不重要，我却用价格打垮你，恒瑞市值突破5500亿</title>
    <updated>2020-12-17T10:10:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/P6fdcEDUef1jigUzcda8IQ</id>
    <link href="https://mp.weixin.qq.com/s/P6fdcEDUef1jigUzcda8IQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PROTAC临床有效性数据公布，之前可以说只是信号</title>
    <updated>2020-12-14T23:35:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/TPcQAqt8n9ihh5Qnyr-vOA</id>
    <link href="https://mp.weixin.qq.com/s/TPcQAqt8n9ihh5Qnyr-vOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021年药品销售TOP 10</title>
    <updated>2020-12-12T07:47:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/kbwrus-rz0q7CW_Eq0plfA</id>
    <link href="https://mp.weixin.qq.com/s/kbwrus-rz0q7CW_Eq0plfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>License in, 与创新无关！</title>
    <updated>2020-12-11T15:24:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/1MRqyFuJGz-0RGhF8Yx6bA</id>
    <link href="https://mp.weixin.qq.com/s/1MRqyFuJGz-0RGhF8Yx6bA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>EGFR-MET双抗Amivantamab(JNJ-61186372)提交上市申请，基于1期结果</title>
    <updated>2020-12-03T23:17:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/eHz_U4bKZq-VK_1NowYyKQ</id>
    <link href="https://mp.weixin.qq.com/s/eHz_U4bKZq-VK_1NowYyKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>